Your browser doesn't support javascript.
loading
Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment
Luo, Jia; Yuan, Ming; Li, Shan; Chen, Lijuan; Zhou, Mingsha; Li, Hailan; Bai, Xiuyuan; Zhang, Zhiyu; Zeng, Weiqi; Sun, Xueyi; Zhang, Qiongfang; Chen, Yi; Zhou, Li.
Afiliação
  • Luo, Jia; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
  • Yuan, Ming; Chongqing Medical and Pharmaceutical College. Chongqing. CN
  • Li, Shan; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
  • Chen, Lijuan; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
  • Zhou, Mingsha; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
  • Li, Hailan; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
  • Bai, Xiuyuan; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Zhang, Zhiyu; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Zeng, Weiqi; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Sun, Xueyi; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Zhang, Qiongfang; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Chen, Yi; Chongqing Medical University. School of Public Health. Chongqing. CN
  • Zhou, Li; Chongqing Medical University. School of Public Health. Department of Epidemiology. Chongqing. CN
Article em En | LILACS-Express | LILACS | ID: biblio-1559111
Biblioteca responsável: BR1.1
ABSTRACT
ABSTRACT Despite good hepatitis B virus (HBV) inhibition by nucleoside analogs (NAs), cases of hepatocellular carcinoma (HCC) still occur. This study proposed a non-invasive predictive model to assess HCC risk in patients with chronic hepatitis B (CHB) receiving NAs treatment. Data were obtained from a hospital-based retrospective cohort registered on the Platform of Medical Data Science Academy of Chongqing Medical University, from 2013 to 2019. A total of 501 patients under NAs treatment had their FIB-4 index updated semiannually by recalculation based on laboratory values. Patients were divided into three groups based on FIB-4 index values < 1.45, 1.45-3.25, and ≥ 3.25. Subsequently, HCC incidence was reassessed every six months using Kaplan-Meier curves based on the updated FIB-4 index. The median follow-up time of CHB patients after receiving NAs treatment was 2.5 years. HCC incidences with FIB-4 index < 1.45, 1.45-3.25, and ≥ 3.25 were 1.18%, 1.32%, and 9.09%, respectively. Dynamic assessment showed that the percentage of patients with FIB-4 index < 1.45 significantly increased semiannually (P < 0.001), and of patients with FIB-4 index ≥ 3.25 significantly decreased (P < 0.001). HCC incidence was the highest among patients with FIB-4 index ≥ 3.25. The FIB-4 index effectively predicted HCC incidence, and its dynamic assessment could be used for regular surveillance to implement early intervention and reduce HCC risk.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Idioma: En Revista: Rev. Inst. Med. Trop. São Paulo (Online) Assunto da revista: Medicina Tropical Ano de publicação: 2024 Tipo de documento: Article / Project document País de afiliação: China País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: LILACS Idioma: En Revista: Rev. Inst. Med. Trop. São Paulo (Online) Assunto da revista: Medicina Tropical Ano de publicação: 2024 Tipo de documento: Article / Project document País de afiliação: China País de publicação: Brasil